Held by 8 specialist biotech funds
High Convergence# Signal Note: OrbiMed Initiates $84.8M Position in Disc Medicine (IRON) OrbiMed's new stake suggests conviction in Disc's pipeline, likely centered on its lead asset slednetug (DISC-0974), an oral hepcidin agonist for iron overload disorders including beta-thalassemia and myelodysplastic syndrome-related iron overload.
AI analyst context — unlock full analysis
## Baker Bros. Initiates Significant New Position in Disc Medicine (IRON) Baker Bros. Advisors, known for high-conviction concentrated bets in biotech, opened a new position of 337,050 shares in Disc Medicine, a hematology-focused company developing bitopertin (a GlyT1 inhibitor) for polycythemia vera and erythropoietic protoporphyria, with pivotal Phase 3 data readouts expected in 2025. The ~$26.8M position from a fund with a strong track record of anticipating clinical and regulatory inflections suggests conviction in upcoming catalysts, likely the AURORA Phase 3 trial in PV where bitopertin targets a large underserved market beyond hydroxyurea. Given Baker Bros.' history of sizing positions around de-risked binary events, this initiation warrants close monitoring into mid-2025
+ 6more — see how much conviction went in
See the Full Story